Unpacking the Potential of HER3-Targeted Therapy in NSCLC

Decera Clinical Education Oncology Podcast · Dec 26, 2023 · 15m

This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including:

Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial

The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab

The HER2xHER3 bispecific antibody zenocutuzumab

The HER3-targeted antibody–drug conjugate SHR-A2009

Presenters in this series include:

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine

Harvard Medical School

Medical Oncology

Massachusetts General Hospital

Boston, Massachusetts

Helena Yu, MD

Associate Attending…